New role for human α-defensin 5 in the fight against hypervirulent Clostridium difficile strains

Infection and Immunity

Volumn 83, Issue 3, 2015, Pages 986-995

  Furci, Lucinda ^a   Baldan, Rossella ^a   Bianchini, Valentina ^a   Trovato, Alberto ^a   Ossi, Cristina ^a   Cichero, Paola ^a   Cirillo, Daniela M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ALPHA DEFENSIN 1; ALPHA DEFENSIN 5; UNCLASSIFIED DRUG; VIRULENCE FACTOR; ALPHA-DEFENSIN 5, HUMAN; ANTIINFECTIVE AGENT; HUMAN NEUTROPHIL PEPTIDE 1;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL VIABILITY; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL MEMBRANE DEPOLARIZATION; CELL SURFACE; COLONY FORMING UNIT; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FLUORESCENCE ACTIVATED CELL SORTING; GERMINATION; IC50; MEMBRANE DEPOLARIZATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; CELL MEMBRANE; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MEMBRANE POTENTIAL; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PSEUDOMEMBRANOUS COLITIS; RIBOTYPING; ULTRASTRUCTURE;

ALPHA-DEFENSINS; ANTI-BACTERIAL AGENTS; CELL MEMBRANE; CLOSTRIDIUM DIFFICILE; ENTEROCOCCUS FAECALIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ESCHERICHIA COLI; HUMANS; MEMBRANE POTENTIALS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; RIBOTYPING;

EID: 84923039622     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02955-14     Document Type: Article

References (64)

1. Dubberke ER, Olsen MA. 2012. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 55(Suppl 2):S88-S92. http://dx.doi.org/10.1093/cid/cis335.
2. Ananthakrishnan AN. 2011. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 8:17-26. http://dx.doi.org/10.1038/nrgastro.2010.190.
3. Sammons JS, Localio R, Xiao R, Coffin SE, Zaoutis T. 2013. Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis 57:1-8. http://dx.doi.org/10.1093/cid/cit155.
4. Walker AS, Eyre DW, Wyllie DH, Dingle KE, Griffiths D, Shine B, Oakley S, O'Connor L, Finney J, Vaughan A, Crook DW, Wilcox MH, Peto TE. 2013. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis 56: 1589-1600. http://dx.doi.org/10.1093/cid/cit127.
5. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ. 2011. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377:63-73. http://dx.doi.org/10.1016/S0140-6736(10)61266-4.
6. Spigaglia P, Barbanti F, Dionisi AM, Mastrantonio P. 2010. Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018. J Clin Microbiol 48:2892-2896. http://dx.doi.org/10.1128/JCM.02482-09.
7. Baldan R, Cavallerio P, Tuscano A, Parlato C, Fossati L, Moro M, Serra R, Cirillo DM. 2010. First report of hypervirulent strains polymerase chain reaction ribotypes 027 and 078 causing severe Clostridium difficile infection in Italy. Clin Infect Dis 50:126-127. http://dx.doi.org/10.1086/649011.
8. Tenover FC, Akerlund T, Gerding DN, Goering RV, Bostrom T, Jonsson AM, Wong E, Wortman AT, Persing DH. 2011. Comparison of strain typing results for Clostridium difficile isolates from North America. J Clin Microbiol 49:1831-1837. http://dx.doi.org/10.1128/JCM.02446-10.
9. Kachrimanidou M, Malisiovas N. 2011. Clostridium difficile infection: a comprehensive review. Crit Rev Microbiol 37:178-187. http://dx.doi.org/10.3109/1040841X.2011.556598.
10. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. 2008. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197:435-438. http://dx.doi.org/10.1086/525047.
11. Madan R, Petri WA, Jr. 2012. Immune responses to Clostridium difficile infection. Trends Mol Med 18:658-666. http://dx.doi.org/10.1016/j.molmed.2012.09.005.
12. Hiemstra PS, Zaat SA. 2013. Antimicrobial peptides and innate immunity. Springer, Basel, Switzerland.
13. Lehrer RI, Lu W. 2012. α-Defensins in human innate immunity. Immunol Rev 245:84-112. http://dx.doi.org/10.1111/j.1600-065X.2011.01082.x.
14. Salzman NH. 2011. Microbiota-immune system interaction: an uneasy alliance. Curr Opin Microbiol 14:99-105. http://dx.doi.org/10.1016/j.mib.2010.09.018.
15. Ghosh D, Porter E, Shen B, Lee SK, Wilk D, Drazba J, Yadav SP, Crabb JW, Ganz T, Bevins CL. 2002. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol 3:583-590. http://dx.doi.org/10.1038/ni797.
16. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P. 2007. Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood 109:2928-2935. http://dx.doi.org/10.1182/blood-2006-05-024489.
17. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ. 2004. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophilderived neurotoxin in host defense. Annu Rev Immunol 22:181-215. http://dx.doi.org/10.1146/annurev.immunol.22.012703.104603.
18. Szyk A, Wu Z, Tucker K, Yang D, Lu W, Lubkowski J. 2006. Crystal structures of human alpha-defensins HNP4, HD5, and HD6. Protein Sci 15:2749-2760. http://dx.doi.org/10.1110/ps.062336606.
19. Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjoberg J, Amir E, Teggatz P, Barman M, Hayward M, Eastwood D, Stoel M, Zhou Y, Sodergren E, Weinstock GM, Bevins CL, Williams CB, Bos NA. 2010. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 11:76-83. http://dx.doi.org/10.1038/ni.1825.
20. Eriguchi Y, Takashima S, Oka H, Shimoji S, Nakamura K, Uryu H, Shimoda S, Iwasaki H, Shimono N, Ayabe T, Akashi K, Teshima T. 2012. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of alpha-defensins. Blood 120:223-231. http://dx.doi.org/10.1182/blood-2011-12-401166.
21. Bevins CL, Salzman NH. 2011. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 9:356-368. http://dx.doi.org/10.1038/nrmicro2546.
22. Vaishnava S, Behrendt CL, Ismail AS, Eckmann L, Hooper LV. 2008. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA 105: 20858-20863. http://dx.doi.org/10.1073/pnas.0808723105.
23. Menendez A, Willing BP, Montero M, Wlodarska M, So CC, Bhinder G, Vallance BA, Finlay BB. 2013. Bacterial stimulation of the TLRMyD88 pathway modulates the homeostatic expression of ileal Paneth cell alpha-defensins. J Innate Immun 5:39-49. http://dx.doi.org/10.1159/000341630.
24. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H, Jr, Fellermann K, Ganz T, Stange EF, Bevins CL. 2005. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 102:18129-18134. http://dx.doi.org/10.1073/pnas.0505256102.
25. Salzman NH, Ghosh D, Huttner KM, Paterson Y, Bevins CL. 2003. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 422:522-526. http://dx.doi.org/10.1038/nature01520.
26. Welkon CJ, Long SS, Thompson CM, Jr, Gilligan PH. 1985. Clostridium difficile in patients with cystic fibrosis. Am J Dis Child 139:805-808.
27. Giesemann T, Guttenberg G, Aktories K. 2008. Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology 134:2049-2058. http://dx.doi.org/10.1053/j.gastro.2008.03.008.
28. Vedantam G, Clark A, Chu M, McQuade R, Mallozzi M, Viswanathan VK. 2012. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes 3:121-134. http://dx.doi.org/10.4161/gmic.19399.
29. Hasegawa M, Yamazaki T, Kamada N, Tawaratsumida K, Kim YG, Nunez G, Inohara N. 2011. Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. J Immunol 186:4872-4880. http://dx.doi.org/10.4049/jimmunol.1003761.
30. Jarchum I, Liu M, Shi C, Equinda M, Pamer EG. 2012. Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis. Infect Immun 80:2989-2996. http://dx.doi.org/10.1128/IAI.00448-12.
31. Koprivnjak T, Peschel A. 2011. Bacterial resistance mechanisms against host defense peptides. Cell Mol Life Sci 68:2243-2254. http://dx.doi.org/10.1007/s00018-011-0716-4.
32. McBride SM, Sonenshein AL. 2011. Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile. Infect Immun 79:167-176. http://dx.doi.org/10.1128/IAI.00731-10.
33. McQuade R, Roxas B, Viswanathan VK, Vedantam G. 2012. Clostridium difficile clinical isolates exhibit variable susceptibility and proteome alterations upon exposure to mammalian cationic antimicrobial peptides. Anaerobe 18:614-620. http://dx.doi.org/10.1016/j.anaerobe.2012.09.004.
34. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 40:2562-2566.
35. Carman RJ, Genheimer CW, Rafii F, Park M, Hiltonsmith MF, Lyerly DM. 2009. Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea. Anaerobe 15:244-248. http://dx.doi.org/10.1016/j.anaerobe.2009.09.009.
36. Porter EM, van Dam E, Valore EV, Ganz T. 1997. Broad-spectrum antimicrobial activity of human intestinal defensin 5. Infect Immun 65: 2396-2401.
37. Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME. 1989. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest 84:553-561.
38. Nuding S, Fellermann K, Wehkamp J, Mueller HA, Stange EF. 2006. A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J Microbiol Methods 65:335-345. http://dx.doi.org/10.1016/j.mimet.2005.08.004.
39. Wehkamp J, Schmid M, Stange EF. 2007. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol 23:370-378. http://dx.doi.org/10.1097/MOG.0b013e328136c580.
40. Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S. 2010. Health careassociated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 50:194-201. http://dx.doi.org/10.1086/649213.
41. Drudy D, Harnedy N, Fanning S, Hannan M, Kyne L. 2007. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol 28:932-940. http://dx.doi.org/10.1086/519181.
42. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan G, Wren BW. 2009. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 10:R102. http://dx.doi.org/10.1186/gb-2009-10-9-r102.
43. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. 2010. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23:529-549. http://dx.doi.org/10.1128/CMR.00082-09.
44. Nuding S, Fellermann K, Wehkamp J, Stange EF. 2007. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 56:1240-1247. http://dx.doi.org/10.1136/gut.2006.118646.
45. Ericksen B, Wu Z, Lu W, Lehrer RI. 2005. Antibacterial activity and specificity of the six human α-defensins. Antimicrob Agents Chemother 49:269-275. http://dx.doi.org/10.1128/AAC.49.1.269-275.2005.
46. McBride SM, Sonenshein AL. 2011. The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. Microbiology 157:1457-1465. http://dx.doi.org/10.1099/mic.0.045997-0.
47. Friedrich CL, Moyles D, Beveridge TJ, Hancock RE. 2000. Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria. Antimicrob Agents Chemother 44:2086-2092. http://dx.doi.org/10.1128/AAC.44.8.2086-2092.2000.
48. 4(3)-), for the flow cytometric assessment of bacterial viability. FEMS Microbiol Lett 130:165-169. http://dx.doi.org/10.1016/0378-1097(95)00199-F.
49. Nuding S, Zabel LT, Enders C, Porter E, Fellermann K, Wehkamp J, Mueller HA, Stange EF. 2009. Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3. Microbes Infect 11:384-393. http://dx.doi.org/10.1016/j.micinf.2009.01.001.
50. Ho TD, Ellermeier CD. 2011. PrsW is required for colonization, resistance to antimicrobial peptides, and expression of extracytoplasmic function sigma factors in Clostridium difficile. Infect Immun 79:3229-3238. http://dx.doi.org/10.1128/IAI.00019-11.
51. Salzman NH, Chou MM, de Jong H, Liu L, Porter EM, Paterson Y. 2003. Enteric salmonella infection inhibits Paneth cell antimicrobial peptide expression. Infect Immun 71:1109-1115. http://dx.doi.org/10.1128/IAI.71.3.1109-1115.2003.
52. Mastroianni JR, Ouellette AJ. 2009. Alpha-defensins in enteric innate immunity: functional Paneth cell alpha-defensins in mouse colonic lumen. J Biol Chem 284:27848-27856. http://dx.doi.org/10.1074/jbc.M109.050773.
53. Peschel A, Sahl HG. 2006. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 4:529-536. http://dx.doi.org/10.1038/nrmicro1441.
54. Lohner K, Prossnigg F. 2009. Biological activity and structural aspects of PGLa interaction with membrane mimetic systems. Biochim Biophys Acta 1788:1656-1666. http://dx.doi.org/10.1016/j.bbamem.2009.05.012.
55. Huang HW. 2009. Free energies of molecular bound states in lipid bilayers: lethal concentrations of antimicrobial peptides. Biophys J 96:3263-3272. http://dx.doi.org/10.1016/j.bpj.2009.01.030.
56. Shimoda M, Ohki K, Shimamoto Y, Kohashi O. 1995. Morphology of defensin-treated Staphylococcus aureus. Infect Immun 63:2886-2891.
57. Hartmann M, Berditsch M, Hawecker J, Ardakani MF, Gerthsen D, Ulrich AS. 2010. Damage of the bacterial cell envelope by antimicrobial peptides gramicidin S and PGLa as revealed by transmission and scanning electron microscopy. Antimicrob Agents Chemother 54:3132-3142. http://dx.doi.org/10.1128/AAC.00124-10.
58. Rajabi M, Ericksen B, Wu X, de Leeuw E, Zhao L, Pazgier M, Lu W. 2012. Functional determinants of human enteric alpha-defensin HD5: crucial role for hydrophobicity at dimer interface. J Biol Chem 287:21615-21627. http://dx.doi.org/10.1074/jbc.M112.367995.
59. Ayabe T, Satchell DP, Wilson CL, Parks WC, Selsted ME, Ouellette AJ. 2000. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 1:113-118. http://dx.doi.org/10.1038/77783.
60. Davies HA, Borriello SP. 1990. Detection of capsule in strains of Clostridium difficile of varying virulence and toxigenicity. Microb Pathog 9:141-146. http://dx.doi.org/10.1016/0882-4010(90)90088-8.
61. Calabi E, Ward S, Wren B, Paxton T, Panico M, Morris H, Dell A, Dougan G, Fairweather N. 2001. Molecular characterization of the surface layer proteins from Clostridium difficile. Mol Microbiol 40:1187-1199. http://dx.doi.org/10.1046/j.1365-2958.2001.02461.x.
62. Meyer-Hoffert U, Hornef MW, Henriques-Normark B, Axelsson LG, Midtvedt T, Putsep K, Andersson M. 2008. Secreted enteric antimicrobial activity localises to the mucus surface layer. Gut 57:764-771. http://dx.doi.org/10.1136/gut.2007.141481.
63. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407-415. http://dx.doi.org/10.1056/NEJMoa1205037.
64. Yeung AT, Gellatly SL, Hancock RE. 2011. Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci 68:2161-2176. http://dx.doi.org/10.1007/s00018-011-0710-x.